Hospital Universitario Son Dureta
Palma de Mallorca, Balearic Islands, 07014, Spain
NCT Number: NCT00671151
Molecular mechanisms of COPD exacerbations and the modulating effect of low dose theophylline on that inflammation are elucidated in this project. NF-kappa B-dependent pathway and acetylation status of nuclear histones are to be studied.Design: controlled, prospective and randomized study with or without theophylline, a potent HDAC activator.Objectives: 1) To determine NF-kB activation, histone deacetylase (HDAC) and histone acetyl-transferase (HAT) activity in sputum macrophages and blood monocytes during an episode of exacerbation and 3 months later, once stability is achieved. To correlate these measurements with inflammatory and oxidative stress markers and with pulmonary function and clinical variables. 2) To assess the effect of theophylline on previous molecular, functional and clinical data. Method: 25 patients with COPD will be recruited during an episode of exacerbation requiring hospitalization. NF-kB activation, HDAC and HAT activity, markers of inflammation and oxidative stress will be determined with specific assays. These determinations will be repeated once the patient is stable and compared with smokers and non smoker controls with normal lung function
Looking for future studies?
Notify Me40 year–75 year
Male
Interventional
Not applicable
Palma de Mallorca, Balearic Islands, 07014, Spain
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Theophylline 100 mg bid for 3 months
Time frame: 3 months
Time frame: 3 months
Time frame: 3 months
Hospital Universitari Son Dureta
Other
Molecular Mechanisms of COPD Exacerbations. Effect of Low-Dose Theophylline
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00655993
COPD, Chronic Disease
Loma Linda, California, United States
View Trial DetailsNCT00677560
Asthma, Bronchial Diseases
London, United Kingdom
View Trial DetailsNCT03853174
COPD, Chronic Disease
Sousse, Tunisia
View Trial DetailsNCT00147017
Bronchial Diseases, Bronchitis
London, United Kingdom
View Trial Details